Dostarlimab-gxly receives accelerated approval from the FDA for dMMR advanced solid tumours

Share This Post

August 2021: Dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) was given accelerated approval by the Food and Drug Administration for adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumours, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.

The VENTANA MMR RxDx Panel was also authorised by the FDA today as a companion diagnostic device for patients with dMMR solid tumours who are being treated with dostarlimab-gxly.

The GARNET Experiment (NCT02715284), a non-randomized, multicenter, open-label, multi-cohort trial, looked at the efficacy of dostarlimab. The effectiveness population included 209 patients with dMMR recurrent or advanced solid tumours who had progressed after systemic therapy and had no other options.
Overall response rate (ORR) and duration of response (DoR) were the major efficacy outcomes, as established by blinded independent central review in accordance with RECIST 1.1. With a 9.1 percent complete answer rate and a 32.5 percent partial response rate, the ORR was 41.6 percent (95 percent CI: 34.9, 48.6). The median DOR was 34.7 months (range 2.6 to 35.8+), and 95.4 percent of patients had a DOR of less than 6 months.

Fatigue/asthenia, anaemia, diarrhoea, and nausea are the most prevalent side responses in individuals with dMMR solid tumours (20 percent). Anemia, fatigue/asthenia, elevated transaminases, sepsis, and acute renal injury were the most prevalent Grade 3 or 4 adverse events (2%). Pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, and dermatologic toxicity are all immune-mediated adverse events associated with dostarlimab-gxly.

Dostarlimab is given as an intravenous infusion over 30 minutes every three weeks for doses one through four. Dosing is increased to 1,000 mg every 6 weeks starting 3 weeks after dosage 4.



Check details here.

Take second opinion on cancer treatment

Send Details

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient A case report
CAR T-Cell therapy

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report

Claudin18.2-targeted CAR-T cell therapy has shown remarkable potential in treating advanced pancreatic cancer, as highlighted in a recent case report. This innovative approach led to complete remission in a patient with advanced disease, underscoring the promise of targeted immunotherapy. By leveraging the specific expression of Claudin18.2 on cancer cells, this therapy offers a precision-based treatment, heralding a new era in pancreatic cancer management with significant clinical implications.

What is the treatment after BCMA CAR T failed in RR multiple myeloma cases
CAR T-Cell therapy

What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?

For people with relapsed or refractory multiple myeloma, BCMA CAR T-cell therapy might not work. Other treatments, such as bispecific antibodies, other CAR T-cell therapies that target different antigens, and combination regimens with immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, can still be used. OriCAR-017 is another immunotherapy that is under trial and is expected to be launched soon. Clinical trials offer experimental treatments, providing access to novel therapies. Tailored approaches based on patient-specific factors and emerging research are crucial for improving outcomes in this challenging scenario.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy